Shengxi Chen

This inventor holds 11 USPTO granted patents and 2 published patent applications. Top assignees: Arizona State University, Emory University. Active years: 2018-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Shengxi Chen. Retrieved from https://idiyas.com/inventor/shengxi-chen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 2)

% Patents Active = 90.9

Average Co-Inventor Count = 1.3

ph-index = 1

Forward Citations = 12(Granted Patents)

Company Filing History:

10 out of 2,159

Arizona State University

Years Active: 2018-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12577627 - SELECTIVE DETECTION OF DIFFERENT DENGUE VIRUS RNA SEROTYPES USING TANDEM TOEHOLD-MEDIATED DISPLACEMENT REACTIONS (2026-03-17),

2. 12492424 - COMPOSITIONS AND METHODS FOR DETECTING VIRAL NUCLEIC ACIDS (2025-12-09),

3. 12383629 - DNA-affibody-drug nanoparticles for inhibiting the metastasis of cancer cells overexpressing HER2 (2025-08-12),

4. 12110313 - Engineered bacterial ribosome compositions and methods (2024-10-08),

5. 11534333 - Skin-like condoms having active ingredients to enhance a male erection and a female arousal (2022-12-27),

6. 11529257 - Skin-like condoms having active ingredients to enhance a male erection and a female arousal (2022-12-20),

7. 11162147 - Apparatuses and methods for detecting nucleic acids (2021-11-02),

8. 10842664 - Skin-like condoms having active ingredients to enhance a male erection and a female arousal (2020-11-24),

9. 10556875 - Bis-diazeniumdiolate compounds as anti-cancer agents (2020-02-11),

10. 10532109 - Peptide-DNA chimeras for treatment of HER overexpressing cancers (2020-01-14),

11. 10100091 - Fusion protein for HIV-1 gp120 antigen detection (2018-10-16),

Title: Innovations of Shengxi Chen in Cancer Research

Introduction

Shengxi Chen is a prominent inventor based in Chandler, AZ, known for his significant contributions to cancer research. With a total of nine patents to his name, he has made remarkable strides in developing therapeutic agents aimed at combating cancer.

Latest Patents

One of his latest patents involves the creation of DNA-affibody-drug nanoparticles designed to inhibit the metastasis of cancer cells that overexpress the HER2 gene. This innovative therapeutic agent showcases specificity for cancer cells, providing a promising avenue for treatment. The patent details pharmaceutical compositions that include HER-targeting peptides and methods for using these compositions to treat or prevent diseases associated with HER overexpression. Another notable patent focuses on engineered bacterial ribosome compositions and methods. This invention relates to bacterial ribosomes that enhance the incorporation of glycosylated amino acids into proteins, offering potential advancements in protein synthesis.

Career Highlights

Shengxi Chen is affiliated with Arizona State University, where he continues to push the boundaries of research in his field. His work has garnered attention for its potential impact on cancer therapies and protein engineering.

Collaborations

He collaborates with esteemed colleagues such as Sidney M Hecht and Yanmin Zhang, contributing to a dynamic research environment that fosters innovation.

Conclusion

Shengxi Chen's work exemplifies the intersection of innovation and practical application in the fight against cancer. His patents reflect a commitment to advancing medical science and improving patient outcomes.

Profile summary based on public USPTO records.

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents pending: